Trial Profile
DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
- Focus Adverse reactions
- 15 Jul 2021 Following the first 9 patients treated with the above mentioned schedule, the study was amended, dose of Gedatolisib 110mg and 130 mg has added in the treatment.
- 15 Jul 2021 Results published in the Clinical Cancer Research
- 21 Sep 2020 According to results presented at the 45th European Society for Medical Oncology Congress, Carboplatin was initially administered at AUC5 on day 8 and Paclitaxel at 80 mg/m2 on day 8, 15 and 22 and after a protocol amendment on day 1 and day 1, 8 and 15 respectively, in 28d cycles.